Substantial doubt about the company's ability to continue as a going concern.
“In accordance with ASU *No.* *2014*-*15,* "Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic *205*-*40*)", the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within *one* year after the date that the consolidated financial statements are issued. The history of losses, the negative cash flow from operations, and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raise doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
BioKey reported third-quarter license fee revenue of $1.28 million, up 39%, lifting gross margin to 90%. It retired remaining note debt, won a Central Bank of Jordan initiative, and targets profitability with roughly $1.2 million in first-quarter license renewals.
BIO-KEY INTERNATIONAL, INC. reported nine-month revenue of 5,548,305, net loss of 1,667,972 and operating cash outflow of 2,634,682. Management said substantial doubt exists about its ability to continue as a going concern.
BIO-key reported Q3’26 license fee revenue growth of 39%, gross margin improvement to 90%, and an 8% narrowing of net loss to $(886K). Nine-month revenue rose 14% to $5.5M, working capital reached $3.1M, and the company retired its remaining note.
On October 30, 2026, Bio Key International, Inc. stockholders approved issuing up to 1,236,668 common shares upon exercise of warrants issued in the August 10, 2026 warrant inducement transaction.
BIO-key registered resale of up to 1,236,668 common shares issuable upon warrant exercise by Armistice Capital Master Fund Ltd.; full cash exercise would provide approximately $5,020,872.08, while sale proceeds go to the selling stockholder.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. License revenue grew 39% and lifted gross margin to 90%, while 9M revenue rose 14% and net loss improved 42%. International customer wins, a stronger pipeline, and debt retirement support management’s outlook for a solid finish to 2026 and a strong start to 2027. However, Q3 revenue declined 4%, hardware and service revenue fell, SG&A increased, and the warrant inducement generated a $4,502,004 deemed dividend.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Weighted average common shares outstanding (basic and diluted) | 1,036,938 | 1H'26 | — |
| non-recurring custom services revenue | $4,000 | the three months ended June 30, 2026 filing | — |
| recurring maintenance and support revenue | $227,000 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BKYI
this stock
Bio Key International Inc
|
$3.05M | — | +111.8% | — | 13.3% |
|
ALLE
Allegion plc
|
$16.19B | +20.6% | +7.6% | 23.9 | 3.0% |
|
ADT
ADT Inc.
|
$7.23B | +22.7% | +4.7% | — | 2.8% |
|
MSA
MSA Safety Inc
|
$6.71B | +8.8% | +3.7% | 22.4 | 2.9% |
|
BCO
Brinks Co
|
$4.81B | +0.1% | -5.7% | 30.7 | 13.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
BIO-KEY INTERNATIONAL, INC. reported nine-month revenue of 5,548,305, net loss of 1,667,972 and operating cash outflow of 2,634,682. Management said substantial doubt exists about its ability to continue as a going concern.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BKYI | -10.9% | -19.4% | -51.8% | -21.5% | -60.7% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -13.5% | -18.2% | -52.3% | -21.3% | -71.4% |
